Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KARUNA THERAPEUTICS, INC.

(KRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
134.65(c) 129.56(c) 125.52(c) 127.9(c) 123.05(c) Last
129 122 101 076 159 197 321 548 265 730 Volume
+1.88% -3.78% -3.12% +1.90% -3.79% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2,69 M - -
Net income 2021 -166 M - -
Net cash position 2021 322 M - -
P/E ratio 2021 -21,6x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -206 M - -
Net cash position 2022 154 M - -
P/E ratio 2022 -18,0x
Yield 2022 -
Capitalization 3 645 M 3 645 M -
EV / Sales 2021 1 234x
EV / Sales 2022 -
Nbr of Employees 63
Free-Float 92,7%
More Financials
Company
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for... 
More about the company
Ratings of Karuna Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about KARUNA THERAPEUTICS, INC.
11/29Karuna Therapeutics Names Charmaine Lykins Chief Commercial Officer
MT
11/29Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
BU
11/29Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
CI
11/11INSIDER SELL : Karuna Therapeutics
MT
11/10Puretech Health Sells $100 Million Karuna Therapeutics Stake
MT
11/09Karuna Therapeutics, Zai Lab Enter Exclusive License Deal for Psychiatric Drug for Grea..
MT
11/09Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manuf..
PU
11/09Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manuf..
BU
11/09KARUNA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disc..
AQ
11/08Oppenheimer Adjusts Karuna Therapeutics PT to $175 From $148, Maintains Outperform Rati..
MT
11/08Karuna Therapeutics to Present at Upcoming Investor Conferences
BU
11/04Wedbush Adjusts Price Target for Karuna Therapeutics to $167 From $164, Maintains Outpe..
MT
11/04KARUNA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/04Karuna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General B..
PU
More news
News in other languages on KARUNA THERAPEUTICS, INC.
11/11VENTE PAR DES INITIÉS : Karuna Therapeutics
11/10Puretech Health vend une participation de 100 millions de dollars dans Karuna Therapeut..
11/09Karuna Therapeutics et Zai Lab concluent un accord de licence exclusive pour un médicam..
10/05VENTE PAR DES INITIÉS : Karuna Therapeutics
More news
Analyst Recommendations on KARUNA THERAPEUTICS, INC.
More recommendations
Chart KARUNA THERAPEUTICS, INC.
Duration : Period :
Karuna Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARUNA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 123,05 $
Average target price 173,85 $
Spread / Average Target 41,3%
EPS Revisions
Managers and Directors
Steven Marc Paul Chairman, President & Chief Executive Officer
Troy A. Ignelzi Chief Financial Officer & Secretary
Stephen Brannan Chief Medical Officer
Inder Kaul Vice President-Clinical Development
Ronald Marcus Senior Vice President-Medical
Sector and Competitors
1st jan.Capi. (M$)
KARUNA THERAPEUTICS, INC.21.12%3 645
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.30.33%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122